Stigler K. A. et al. (2004)
A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders.
Journal of Child and Adolescent Psychopharmacology
14(1), pp. 49-56
Stigler K. A. et al. (2009)
Autism and immune factors: A comprehensive review.
Research in Autism Spectrum Disorders
pp. 840-860
Stigler K. A. , Posey D. J. , McDougle C. J. (2004)
Case report: aripiprazole for maladaptive behavior in pervasive developmental disorder.
Journal of Child and Adolescent Psychopharmacology
14(3), pp. 455-463
Stigler K. A. et al. (2010)
Paliperidone for irritability in autistic disorder.
Journal of Child and Adolescent Psychopharmacology
pp. 75-78
Stigler K. A. , McDougle C. J. (2008)
Pharmacotherapy of irritability in pervasive developmental disorders.
Child and Adolescent Psychiatric Clinics of North America
17(4), pp. 739-752
Psychopharmacologic management of serious behavioral disturbance in ASD.
Child and Adolescent Psychiatric Clinics of North America
January, 23(1), pp. 73-82.
Stigler K. A. , Posey D. J. , McDougle C. J. (2006)
Ramelteon for insomnia in two youths with autistic disorder.
Journal of Child and Adolescent Psychopharmacology
16(5), pp. 631-636
Stigler K. A. , Posey D. J. , McDougle C. J. (2002)
Recent advances in the pharmacotherapy of autism.
Expert Review of Neurotherapeutics
2(4), pp. 499-510
Wink L. K. et al. (2010)
Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.
Expert Opinion on Emerging Drugs
September, 15(3), pp. 481-494